PD-1 Inhibitor and Radiation for Elderly Esophageal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining a PD-1 inhibitor (a type of immunotherapy) with radiation therapy can help older adults (70+) with esophageal squamous cell cancer who cannot have surgery. The goal is to see if this treatment is safe and effective for those with limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 70 years old or older.
- You have a type of esophageal cancer called squamous cell cancer that cannot be removed with surgery or you choose not to have surgery, and you cannot have standard chemo with radiation.
- You have not had any treatment for this cancer before (like surgery, chemotherapy, radiotherapy, or immunotherapy).
- Your cancer is stage II to IVa (meaning it has not spread to distant organs).
- You are in generally good health, with a performance status of 70 or higher on a scale from 0 to 100.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
This study compares a planned radiation approach given at the same time as other treatment for older adults with esophageal squamous cell carcinoma. It may help find a safer and more effective radiation schedule for people who are fit enough for treatment.
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.